Answers are grounded in this paper and cite their sources.
Introduction. Combination of proton pump inhibitor and prokinetic has been found to be the most promising strategy for managing the monopathology of both gastroesophageal reflux disease (GERD) and functional dyspepsia (FD). However, in literature there are only single studies devoted to the effect of the rabeprazole + acotiamide combination on the GERD – FD overlap. Aim. To evaluate the efficacy of 4-week therapy with a combination of rabeprazole 20 mg/day + acotiamide 100 mg three times a day in patients with GERD – FD overlap. Materials and methods. We conducted a single-site, prospective, open-label, observational, non-comparative study OVERLAP. The treatment results were assessed on the basis of an analysis of changes in the GERD and FD symptoms frequency, severity (Likert scale), and mFSSG scores; QoL testing using the SF-8 and SF-NDI questionnaires; comparison of baseline and final 24-h pH-impedance, EGDS measurements; assessment of patient and physician satisfaction with treatment; and treatment tolerability. Results. GERD-associated symptoms were relieved in 96.7% of patients, while FD-associated complaints were relieved in 93.3% of patients. The treatment significantly reduced the AET and DeMeester scores. Separate analysis of reflux phenotype dynamics revealed a 2.2-fold decrease in acid reflux, a 1.7-fold decrease in non-acid reflux, a 1.9-fold decrease in liquid reflux, and a 1.6-fold decrease in mixed reflux. The patients demonstrated essential enhancement of protective mechanisms: a significant increase in the post-reflux swallow-induced peristaltic wave index and mean nocturnal baseline impedance at Z1 with a decrease in the bolus exposure time. The pronounced positive changes in all quality-of-life parameters were reported. Conclusion. Rabeprazole Razo® and acotiamide Dyspevict® combination therapy led to regression of clinical manifestations and improved the quality of life in patients with GERD and FD. The suppression of gastric hypersecretion and elimination of motorevacuation dysfunction formed the pathogenic basis for positive clinical response. The combination is safe, well-tolerated, and can be recommended for common use in patients with GERD and FD.
No takes yet. Share an insight, caveat, or question.
Onuchina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: